Efficacy and safety of brigatinib in first-line treatment
of ALK-positive non-small cell lung cancer (NSCLC).
PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY
Instructions
Contact
Contact for the Organizer:
BioStat Sp. z o.o.
ul. Kowalczyka 17, 44-206 Rybnik
+48 530 714 118,
[email protected]
Contracts and payments:
Monika Mierzyńska
+48 32 44 027 07,
[email protected]
close
Access key